People who may benefit from geographic atrophy treatment are those with confirmed geographic atrophy caused by age-related macular degeneration (AMD) who want to slow, rather than reverse, damage to the retina. Eye specialists consider the affected area's size and location, how the condition is changing, vision in each eye, other eye conditions, and whether a person can attend repeated injections and follow-up visits. Treatment is not right for everyone.
Who is a potential candidate for geographic atrophy treatment?
Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration that damages light-sensitive cells and supporting tissue in the retina. As the damaged areas enlarge, they can affect central vision used for reading, recognizing faces, and seeing fine details.
Two injectable medicines are approved by the U.S. Food and Drug Administration (FDA) to treat geographic atrophy associated with AMD: pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay). These medicines aim to slow the growth of damaged areas rather than repair retinal cells that have already been lost. A person with confirmed GA may wish to discuss these options with a retinal specialist, but a diagnosis alone does not mean that injections are the best choice.
According to the American Academy of Ophthalmology, these treatments can slow the progression of geographic atrophy, but they do not restore lost vision or prevent all future vision loss. Their potential value therefore depends partly on whether slowing the condition's progression offers a meaningful benefit for the individual.
Which factors influence whether treatment may be worthwhile?
There is no single feature that makes treatment the right choice for everyone. A retinal specialist considers the findings from an eye examination alongside the person's vision, medical history, preferences, and ability to continue treatment over time.
Several factors may be relevant when discussing treatment:
- Confirmed geographic atrophy due to AMD: The medicines are intended for this specific condition. Other causes of retinal damage may require a different approach.
- The size and location of the damaged area: The specialist considers how much of the retina is affected and how close the damaged area is to the fovea, the central part of the macula responsible for sharp vision.
- Changes seen on retinal scans: Comparing images over time can help the specialist understand whether the affected area is enlarging and how the disease is progressing.
- Vision in each eye: The effect on everyday activities and the amount of useful vision that remains help put potential treatment benefits into perspective.
- Other eye conditions: The presence of wet AMD, inflammation, infection, or other retinal problems may affect treatment planning or safety.
- Willingness and ability to attend regular appointments: These medicines require repeated eye injections and ongoing monitoring, so travel, costs, support needs, and treatment preferences matter.
These factors help guide a shared decision rather than provide a checklist that determines eligibility. Even when geographic atrophy is affecting vision, the likely benefit of slowing further damage must be weighed against treatment risks and the burden of repeated visits.
How do the available injections help?
Syfovre and Izervay work by targeting parts of the complement system, a group of proteins involved in immune activity. This system is thought to contribute to retinal damage in geographic atrophy. By blocking specific complement proteins, the medicines can slow the expansion of areas affected by the disease.
The FDA's Drug Trials Snapshot for Izervay describes its approval for geographic atrophy secondary to AMD and its use as an injection into the eye. In the United States, both Syfovre and Izervay are approved for this condition. Their availability and regulatory status may differ in other countries.
The benefit is limited but may still matter to some patients. Treatment does not bring back retinal cells that have already been destroyed, and it does not guarantee that vision will remain stable. Instead, the goal is to reduce the rate at which affected areas grow. Any potential benefit needs to be considered alongside the person's current vision, retinal findings, and priorities.
Who might not be suitable for these injections?
Not everyone with geographic atrophy can safely receive treatment. Active infection in or around the eye and active inflammation inside the eye are important reasons not to administer these medicines while those problems are present. The prescribing information for Syfovre published by the U.S. National Library of Medicine's DailyMed identifies these conditions as contraindications.
Other considerations include the possibility of infection inside the eye, retinal detachment, inflammation, increased eye pressure, or the development of wet AMD. These complications do not occur in every person, but they are important when deciding whether the potential benefit outweighs the risks. The choice of medicine and the monitoring plan should account for an individual's eye health and treatment history.
A person with substantial vision loss may also need help beyond injections. Treatment is not a way to restore vision already lost, so it is important to discuss what slowing further damage could realistically achieve. Low-vision aids, better lighting, magnification tools, and vision rehabilitation may support daily activities whether or not injections are chosen.
What tests help an eye specialist make the decision?
A retinal specialist usually combines an eye examination with imaging and vision tests. The purpose is to confirm the diagnosis, assess where the damaged areas are located, evaluate the condition of the retina, and look for changes that could influence treatment decisions.
According to Mayo Clinic's guidance on geographic atrophy diagnosis and treatment, an assessment may include a dilated eye examination, visual acuity or reading tests, optical coherence tomography (OCT), and fundus autofluorescence imaging. OCT produces detailed images of retinal layers, while fundus autofluorescence helps identify damaged retinal tissue.
Previous scans can be particularly useful because they help show how the affected area has changed over time. The specialist may also assess whether wet AMD is present or develops, since this can change the management plan. The findings from both eyes, other eye conditions, and the person's experience of vision loss all contribute to the discussion.
What should patients consider before starting treatment?
Before deciding, patients can ask their retinal specialist what the treatment is expected to achieve in their particular eye, how the likely benefit will be measured, how often injections and follow-up visits are needed, and what complications require prompt attention. It is also reasonable to discuss treatment costs, insurance coverage, transport to appointments, and the practical demands of continuing care.
Both medicines require repeated injections rather than a single procedure. The schedule depends on the medicine used and the treatment plan. For example, the DailyMed prescribing information for Izervay describes a recurring injection schedule and warns about complications such as infection inside the eye and retinal detachment. Regular follow-up helps the specialist monitor the response and identify problems that need attention.
After an eye injection, new or worsening eye pain, redness, light sensitivity, or blurred vision should be reported to the treating eye clinic without delay. Sudden changes in vision also deserve urgent assessment. These symptoms can have different causes, but prompt evaluation is important because some injection-related complications require timely treatment.
Ultimately, geographic atrophy treatment is a personal decision made with a qualified eye specialist. Someone may reasonably choose injections to try to slow further retinal damage, while another person may decide that the expected benefit, potential risks, appointment schedule, or cost does not fit their circumstances. The aim is to make an informed choice based on the condition of the eyes and the person's priorities, rather than assuming that treatment is necessary for everyone.